• Busulfex is used around the world as a pretreatment prior to hematopoietic stem cell transplantation in patients with hematologic cancers

• The approval in Japan reflects the once-daily usage pattern for Busulfex in adults in other countries

• The addition of a once-daily dosage regimen is expected to reduce the burdens and risks for patients and medical staff

Otsuka Pharmaceutical Co., Ltd. today announces it has received regulatory approval for a once-daily form of Busulfex^® Injection 60 mg (generic name is busulfan). Busulfex is a conditioning regimen administered via intravenous drip to patients prior to undergoing hematopoietic stem cell transplantation.